Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Published on Apr 1, 2015in Nature Reviews Urology14.432
· DOI :10.1038/NRUROL.2015.58
Ashish M. Kamat79
Estimated H-index: 79
 , Thomas W. Flaig41
Estimated H-index: 41
 (CU: University of Colorado Boulder)+ 6 AuthorsJohn A. Taylor16
Estimated H-index: 16
 (UConn: University of Connecticut)
Sources
Abstract
A focus group of specialized urologic oncologists has reviewed guidelines and clinical evidence and discussed their experiences regarding the optimal use of BCG in the management of patients with NIMBC. Here, they provide a review of BCG therapy, clarify complex related topics and recommend best practice guidelines to improve BCG use and patient outcomes.
📖 Papers frequently viewed together
201446.80Nature Reviews Gastroenterology & Hepatology
12 Authors (Colin Hill, ..., Mary Ellen Sanders)
201514.43Nature Reviews Urology
9 Authors (Thomas W. Flaig, ..., John A. Taylor)
20007.45The Journal of Urology
12 Authors (Donald L. Lamm, ..., E. David Crawford)
References1821
Newest
Apr 1, 2015·The Journal of Urology7.45
#1Alvaro Morales (Queen's University)H-Index: 61
#2Harry W. Herr (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 114
Last. Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 79
view all 7 authors...
Purpose: Patients with high risk recurrences after bacillus Calmette-Guerin failure have limited options. We performed an open label study to evaluate the efficacy and safety of intravesical MCNA in this setting.Materials and Methods: Patients were treated intravesically with 8 mg MCNA weekly for 6 weeks followed by 3 weekly instillations at months 3, 6, 12, 18 and 24. Cystoscopy and cytology were performed every 3 months for 2 years with mandatory biopsy at 6 months and as clinically indicated ...
Source
#1Susan E. HowlettH-Index: 46
#2HM FillitH-Index: 1
Last. K WoodhouseH-Index: 1
view all 4 authors...
Source
Aug 1, 2014·The Journal of Urology7.45
#1Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 79
#2J. Alfred Witjes (Radboud University Nijmegen Medical Centre)H-Index: 89
Last. Joan Palou (Autonomous University of Barcelona)H-Index: 42
view all 10 authors...
Purpose: Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS). However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the m...
Source
Jul 1, 2014·Journal of Biomedical Nanotechnology4.10
#1Cho SkH-Index: 1
#2Kazunori EmotoH-Index: 2
Last. Wounjhang ParkH-Index: 31
view all 6 authors...
: Nanomaterial-directed, photothermal ablation is a practical future approach for the treatment of early-stage bladder cancer. Using a new PEGylation technique with bi-functional nitrophenyl carbonate PEG (bi-NPC-PEG) that promotes uniform suspension of the nanomaterial in solution, we have shown that gold nanorods conjugated to an anti-EGFR antibody (nano-alphaEGFR) bind effectively to EGFR-expressing bladder cancer cells. The subsequent application of infrared light, specifically tuned to the ...
Source
Apr 1, 2014·International Journal of Radiation Oncology Biology Physics7.04
#1Phillip J. Gray (Harvard University)H-Index: 10
#2Chun Chieh Lin (ACS: American Cancer Society)H-Index: 23
Last. Jason A. Efstathiou (Harvard University)H-Index: 57
view all 12 authors...
Purpose To examine the accuracy of clinical staging and its effects on outcome in bladder cancer (BC) patients treated with radical cystectomy (RC), using a large national database. Methods and Materials A total of 16,953 patients with BC without distant metastases treated with RC from 1998 to 2009 were analyzed. Factors associated with clinical–pathologic stage discrepancy were assessed by multivariate generalized estimating equation models. Survival analysis was conducted for patients treated ...
Source
Feb 10, 2014·Cancer Cell31.74
#1Woonyoung Choi (University of Texas MD Anderson Cancer Center)H-Index: 29
#2Sima P. Porten (University of Texas MD Anderson Cancer Center)H-Index: 26
Last. David J. McConkey (University of Texas at Austin)H-Index: 113
view all 20 authors...
Summary Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. We discovered three molecular subtypes of MIBC that resembled established molecular subtypes of breast cancer. Basal MIBCs shared biomarkers with basal breast cancers and were characterized by p63 activation, squamous differentiation, and more aggressive disease at presentation. Luminal MIBCs contained features of active PPARγ and e...
Source
Jan 1, 2014·Urologic Oncology-seminars and Original Investigations3.50
#1Andrew J. Lightfoot (UI: University of Iowa)H-Index: 13
#2Benjamin N. Breyer (UCSF: University of California, San Francisco)H-Index: 44
Last. Michael A. O’Donnell (UI: University of Iowa)H-Index: 47
view all 6 authors...
Objective Apart from cystectomy, few treatment options exist for the management of bacillus Calmette-Guerin refractory non–muscle invasive bladder cancer (NMIBC). We report a multi-institutional experience with sequential intravesical combination chemotherapy using gemcitabine and mitomycin C (MMC) for NMIBC in the treatment of high-risk patients.
Source
Jan 1, 2014·Urologic Oncology-seminars and Original Investigations3.50
#1Donald L. LammH-Index: 63
#2Maurizio Brausi (AUSL: Academy for Urban School Leadership)H-Index: 40
Last. J. Alfred Witjes (Radboud University Nijmegen Medical Centre)H-Index: 89
view all 4 authors...
Abstract Objectives In this article, we review the various options for and the potential role of interferon alfa (IFN-α) in the treatment of non–muscle-invasive bladder cancer (NMIBC). Methods PubMed was searched for journal articles on IFN-α use in treating bladder cancer. The references listed in the National Comprehensive Cancer Network guidelines were used as a guide to identify relevant publications on treatments for NMIBC. Results Transurethral resection with adjuvant intravesical chemothe...
Source
Any law in which a physical quantity varies with distance from a source inversely as the square of …
Source
Dec 1, 2013·Catheterization and Cardiovascular Interventions2.69
#1Itsik Ben-Dor (MedStar Washington Hospital Center)H-Index: 35
#2Gabriel Maluenda (MedStar Washington Hospital Center)H-Index: 27
Last. Ron Waksman (MedStar Washington Hospital Center)H-Index: 100
view all 10 authors...
Background: Coronary artery disease often coexists with severe aortic stenosis. The feasibility and safety of combined balloon aortic valvuloplasty (BAV) and percutaneous coronary intervention (PCI) are unknown. Aim: To compare outcomes and complications of combined BAV and PCI with BAV alone. Methods: The study cohort consisted of 409 patients with severe aortic stenosis undergoing BAV from 1/2007 to 12/2010. Overall, 329 patients underwent BAV alone and 80 underwent concomitant PCI. Clinical a...
Source
12345678910
Cited By159
Newest
Dec 1, 2021·African Journal of Urology
#1Nassib Abou Heidar (AUB: American University of Beirut)H-Index: 4
#2Muhieddine Labban (AUB: American University of Beirut)H-Index: 4
Last. Rami Nasr (AUB: American University of Beirut)H-Index: 7
view all 7 authors...
The optimal surveillance method for recurrence of non-muscle invasive bladder cancer (NMIBC) after intravesical BCG treatment is unknown. The aim of this study is to assess the difference between two surveillance methods: cystoscopy with bladder biopsies and office-based flexible cystoscopy in detecting NMIBC recurrence and time to recurrence. Charts of patients who underwent transurethral resection of bladder tumor with subsequent intravesical Bacillus Calmette–Guerin (BCG) treatment were revie...
Source
Nov 15, 2021·Chemical Society Reviews54.56
#1Qi-Wen Chen (WHU: Wuhan University)H-Index: 4
#2Ji-Yan Qiao (WHU: Wuhan University)
Last. Xian-Zheng Zhang (WHU: Wuhan University)H-Index: 98
view all 5 authors...
Microorganisms have been extensively applied as active biotherapeutic agents or drug delivery vehicles for antitumor treatment because of their unparalleled bio-functionalities. Taking advantage of the living attributes of microorganisms, a new avenue has been opened in anticancer research. The integration of customized functional materials with living microorganisms has demonstrated unprecedented potential in solving existing questions and even conferring microorganisms with updated antitumor a...
Source
#2Mahendra BishnoiH-Index: 30
#3Kanthi Kiran KondepudiH-Index: 19
Source
#1Justine Vily-PetitH-Index: 2
#2A. BarataudH-Index: 3
Last. Gilles MithieuxH-Index: 53
view all 6 authors...
Source
#1Zhao Yang (Xinjiang Production and Construction Corps)H-Index: 3
#5Haifeng Wang (Kunming Medical University)H-Index: 3
Background and aim Urothelial bladder cancer (UBC) is a common malignant tumor of the urogenital system with a high rate of recurrence. Due to the sophisticated and largely unexplored mechanisms of tumorigenesis of UBC, the classical therapeutic approaches including transurethral resection and radical cystectomy combined with chemotherapy have remained unchanged for decades. However, with increasingly in-depth understanding of the microenvironment and the composition of tumor-infiltrating lympho...
Jul 1, 2021·World Journal of Urology4.23
#1Wojciech Krajewski (Wrocław Medical University)H-Index: 12
#2Marco MoschiniH-Index: 28
Last. Romuald Zdrojowy (Wrocław Medical University)H-Index: 14
view all 31 authors...
Purpose This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette-Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC). Materials and methods Data on 429 patients from 13 tertiary care centers with primary T1HG NMIBC treated with reTURB and maintena...
Source
#1David R. Holmes (Mayo Clinic)H-Index: 192
Percutaneous techniques have become the dominant revascularization strategy for the treatment of patients with both acute and chronic coronary artery disease. They have been studied in multiple registries and randomized clinical trials using as comparators medical therapy and coronary bypass graft surgery.
Abstract Objective To compare the differences in adverse effects and efficacy profile between bacillus Calmette–Guerin (BCG) Danish 1331 and BCG Moscow-I strain in management of non-muscle invasive bladder cancer (NMIBC). Methods Clinical data of 188 cases of NMIBC treated with BCG between 2008 and 2018 in our institute were collected prospectively and analysed retrospectively, and 114 patients who completed a minimum of 12 months of follow-up were analysed. Patient and tumor characters, strain ...
Source
May 11, 2021·Seminars in Cancer Biology15.71
#1Vipin Chandra Kalia (Konkuk University)H-Index: 53
#2Sanjay K.S. Patel (Konkuk University)H-Index: 35
Last. Jung-Kul Lee (Konkuk University)H-Index: 57
view all 5 authors...
Bacteria are associated with the human body and colonize the gut, skin, and mucous membranes. These associations can be either symbiotic or pathogenic. In either case, bacteria derive more benefit from their host. The ability of bacteria to enter and survive within the human body can be exploited for human benefit. They can be used as a vehicle for delivering or producing bioactive molecules, such as toxins and lytic enzymes, and eventually for killing tumor cells. Clostridium and Salmonella hav...
Source
Apr 2, 2021·Frontiers in Oncology6.24
#1Sahyun PakH-Index: 7
#2Sun Young KimH-Index: 23
Last. Kang Hyun LeeH-Index: 14
view all 8 authors...
Objective: To investigate the association between antibiotic therapy and the efficacy of intravesical BCG therapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). Methods: This study involved the retrospective review of medical records of patients who underwent transurethral resection of bladder tumors for high-risk NMIBC followed by intravesical BCG therapy between 2008 and 2017. Patients were categorized as none, short- (2-6 days), and long-course use (≥7 days) based on t...
Source
12345678910
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.